COVID-19 所致 ARDS 的免疫亚表型与恢复期血浆治疗反应:CONFIDENT 试验的二次分析
该研究为 CONFIDENT 试验的二次分析,在纳入 CONFIDENT 的 475 例 COVID-19 所致 ARDS 患者中,对同意参与本二次研究的中心患者于入组时用多重技术检测 20 种细胞因子、趋化因子和细胞黏附标志物的 391 例(82%)进行了检测,其中 196/391(50.1%)被分配至恢复期血浆组。无监督层次聚类分析识别出 4 种亚表型,分别占 89 例(22.8%)、178 例(45.5%)、38 例(9.7%)和 86 例(22.0%);主成分分析中贡献最大的生物标志物为 IL-1β、IL-12p70、IL-6、IFN-α、IL-17A、IFN-γ、IL-13、TFN-α、总 IgG 和 CXCL10。亚表型-2 和亚表型-4 在纳入时病情严重程度更高;恢复期血浆对死亡率的影响在各亚表型中似乎均高于标准治疗,亚表型间无显著异质性(p=0.97)。结论认为,基于免疫反应识别的 4 种亚表型与不同临床特征相关,但恢复期血浆的治疗反应在 4 种亚表型间相似。
要点
- 在 COVID-19 所致 ARDS 患者中,基于 20 种免疫标志物可聚类出 4 种免疫亚表型,分别占 22.8%、45.5%、9.7% 和 22.0%。
- 亚表型-2 和亚表型-4 在纳入时病情严重程度更高,提示免疫表型与临床严重度相关。
- 恢复期血浆对 28 天死亡率的影响在各亚表型中似乎均高于标准治疗,亚表型间无显著异质性(p=0.97)。
- 主成分分析中贡献最大的标志物包括 IL-1β、IL-12p70、IL-6、IFN-α、IL-17A、IFN-γ、IL-13、TFN-α、总 IgG 和 CXCL10。
适用人群与场景
- CONFIDENT 试验纳入的 COVID-19 所致 ARDS 患者,且所在中心同意参与本二次分析并完成入组时生物标志物采样者。
研究设计与关键结果
- 研究类型:CONFIDENT 试验的二次分析;在纳入 CONFIDENT 的 475 例患者中,391 例(82%)完成采样,其中 196/391(50.1%)被分配至恢复期血浆组。
- 通过无监督层次聚类识别出 4 种亚表型,分别占 89 例(22.8%)、178 例(45.5%)、38 例(9.7%)和 86 例(22.0%)。
- 主成分分析中贡献最大的生物标志物为 IL-1β、IL-12p70、IL-6、IFN-α、IL-17A、IFN-γ、IL-13、TFN-α、总 IgG 和 CXCL10。
- 亚表型-1 免疫反应较低;亚表型-2 适应性反应较高;亚表型-3 先天抗病毒、促炎和抗炎反应及黏附分子活化最高;亚表型-4 促炎和抗炎反应、迁移蛋白及黏附分子活化较高。
- 亚表型-2 和亚表型-4 在纳入时病情严重程度更高。
- 恢复期血浆对死亡率的影响在各亚表型中似乎均高于标准治疗,亚表型间无显著异质性(p=0.97)。
证据类型、等级与局限
- 证据类型:随机对照试验(CONFIDENT)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在 COVID-19 所致 ARDS 患者中识别出的 4 种免疫亚表型与不同临床特征相关,但恢复期血浆的治疗反应在 4 种亚表型间相似,未提示需根据免疫亚表型选择恢复期血浆治疗。
指南或共识出处
- CONFIDENT 试验(ClinicalTrials.gov NCT04558476,注册日期 2020-09-11;伦理委员会:列日大学医院 CE 2020/239)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Convalescent plasma (CP) reduced the mortality in COVID-19 induced ARDS (C-ARDS) patients treated in the CONFIDENT trial. As patients are immunologically heterogeneous, we hypothesized that clusters may differ in their treatment responses to CP.
METHODS: We measured 20 cytokines, chemokines and cell adhesion markers using a multiplex technique at the time of inclusion in the CONFIDENT trial in patients of centers having accepted to participate in this secondary study. We performed descriptive statistics, unsupervised hierarchical cluster analysis, and examined the association between the clusters and CP effect on day-28 mortality.
RESULTS: Of the 475 patients included in CONFIDENT, 391 (82%) were sampled, and 196/391 (50.1%) had been assigned to CP. We identified four sub-phenotypes representing 89 (22.8%), 178 (45.5%), 38 (9.7%), and 86 (22.0%) patients. The most contributing biomarkers in the principal component analysis were IL-1β, IL-12p70, IL-6, IFN-α, IL-17A, IFN-γ, IL-13, TFN-α, total IgG, and CXCL10. Sub-phenotype-1 displayed a lower immune response, sub-phenotype-2 a higher adaptive response, sub-phenotype-3 the highest innate antiviral, pro and anti-inflammatory response, and adhesion molecule activation, and sub-phenotype-4 a higher pro and anti-inflammatory response, migration protein and adhesion molecule activation. Sub-phenotype-2 and sub-phenotype-4 had higher severity at the time of inclusion. The effect of CP treatment on mortality appeared higher than standard care in each sub-phenotype, without heterogeneity between sub-phenotypes (p = 0.97).
CONCLUSION: In patients with C-ARDS, we identified 4 sub-phenotypes based on their immune response. These sub-phenotypes were associated with different clinical profiles. The response to CP was similar across the 4 sub-phenotypes.
TRIAL REGISTRATION: Ethics Committee of the University Hospital of Liège CE 2020/239.
CLINICALTRIALS: gov NCT04558476. Registered 2020-09-11, https://www.
CLINICALTRIALS: gov/study/NCT04558476 .
参考来源
- Misset B, Diep AN, Bertrand A, et al. Immunological sub-phenotypes and response to convalescent plasma in COVID-19 induced ARDS: a secondary analysis of the CONFIDENT trial. Ann Intensive Care. 2024. PMID: 39432177. doi:10.1186/s13613-024-01392-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。